BioCentury | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

...double-digit royalties. Novan gets $25M to start Phase III testing Reedy Creek Investments will provide Novan Inc....
...of payments, milestones and royalties that Novan receives for dermatology candidates SB206, SB414 and SB204. Novan...
...PM1183, tryptamicidin) AbbVie Inc. Amgen Inc. Bayer AG EirGenix Inc. G1 Therapeutics Inc. Johnson & Johnson Luye Pharma Group Ltd. Merck & Co. Inc. Novan Inc. Novartis...
BioCentury | Sep 7, 2018
Clinical News

Novan's nitric oxide-releasing cream formulation improves itch in atopic dermatitis

...for vehicle control in a Phase Ib trial to treat mild to moderate atopic dermatitis. Novan...
...were safe with no serious adverse events reported. SB414 is a nitric oxide-releasing cream formulation. Novan Inc....
...rating scale (NRS) and Eczema Area Severity Index (EASI) Status: Phase Ib data Milestone: NA Chris Lieu SB414 Novan Inc. Psoriasis Dermatitis...
BioCentury | Mar 23, 2018
Company News

Management tracks: Sienna, Origenis

...the end of April. He will be succeeded by John Smither, who was CFO at Novan Inc....
BioCentury | Jan 6, 2018
Financial News

Novan raises $38M follow-on

...a 12% discount to Novan's close of $4.30 on Wednesday, before it proposed the follow-on. Novan...
...pharmacokinetic trial of the topical NO-releasing compound. Novan lost $0.88 (21%) to $3.36 on Friday. Alicia Parker Novan Inc....
BioCentury | Apr 14, 2017
Clinical News

SB208: Ph II NI-AF201 data

...and 74.2% had negative fungal culture in the 16% group (p=0.016) vs. 45.5% for placebo. Novan...
...fungal culture at day 14 in 61.3% of patients, but did not disclose a p-value. Novan...
...in the mid-dose group (50%, p=0.009) and high-dose group (53.1%, p=0.01) vs. 23.5 for vehicle. Novan...
BioCentury | Apr 12, 2017
Clinical News

Novan gains on Phase II athlete's foot readout

...vehicle. Mycological cure was defined as negative tests for both fungal culture and skin scraping. Novan...
...reported only the high dose’s rate of 58.8% (p<0.05 vs. vehicle). Even with Wednesday's gains, Novan...
...all three endpoints in an identical Phase III study. Following further analysis of the data, Novan...
BioCentury | Apr 7, 2017
Finance

Fade to black

...trial shows no efficacy in combination with Keytruda pembrolizumab to treat advanced or recurrent malignancies Novan Inc....
BioCentury | Apr 1, 2017
Company News

Management tracks

...Novan Inc. (NASDAQ:NOVN) and joined Sienna Biopharmaceuticals Inc. (Westlake Village, Calif.), another dermatology play, as CFO. Novan...
...CFO and SVP of finance and administration at Pozen Inc. , as its interim CFO. Novan...
BioCentury | Feb 3, 2017
Clinical News

SB204: Ph III NI-AC301 and NI-AC302 data

...to develop and commercialize SB204 in Japan to treat acne (see BioCentury, Jan. 23 ). Novan Inc....
...lesion count and time to improvement in IGA Status: Phase III data Milestone: NA Jaime De Leon NVN1000 SB204 Novan Inc. Sato...
BioCentury | Jan 27, 2017
Clinical News

Novan pummeled on Phase III acne miss

...oxide (NO)-releasing compound showed significant efficacy on all three measures in NI-AC302 (p<0.05 for all). Novan...
...on its plans for SB204. Novan declined to comment on the timing of that update. Novan...
...its September 2016 IPO at $11. Its shares traded above $30 on Dec. 7. Jaime De Leon NVN1000 SB204 Novan Inc. Androgen...
Items per page:
1 - 10 of 34
BioCentury | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

...double-digit royalties. Novan gets $25M to start Phase III testing Reedy Creek Investments will provide Novan Inc....
...of payments, milestones and royalties that Novan receives for dermatology candidates SB206, SB414 and SB204. Novan...
...PM1183, tryptamicidin) AbbVie Inc. Amgen Inc. Bayer AG EirGenix Inc. G1 Therapeutics Inc. Johnson & Johnson Luye Pharma Group Ltd. Merck & Co. Inc. Novan Inc. Novartis...
BioCentury | Sep 7, 2018
Clinical News

Novan's nitric oxide-releasing cream formulation improves itch in atopic dermatitis

...for vehicle control in a Phase Ib trial to treat mild to moderate atopic dermatitis. Novan...
...were safe with no serious adverse events reported. SB414 is a nitric oxide-releasing cream formulation. Novan Inc....
...rating scale (NRS) and Eczema Area Severity Index (EASI) Status: Phase Ib data Milestone: NA Chris Lieu SB414 Novan Inc. Psoriasis Dermatitis...
BioCentury | Mar 23, 2018
Company News

Management tracks: Sienna, Origenis

...the end of April. He will be succeeded by John Smither, who was CFO at Novan Inc....
BioCentury | Jan 6, 2018
Financial News

Novan raises $38M follow-on

...a 12% discount to Novan's close of $4.30 on Wednesday, before it proposed the follow-on. Novan...
...pharmacokinetic trial of the topical NO-releasing compound. Novan lost $0.88 (21%) to $3.36 on Friday. Alicia Parker Novan Inc....
BioCentury | Apr 14, 2017
Clinical News

SB208: Ph II NI-AF201 data

...and 74.2% had negative fungal culture in the 16% group (p=0.016) vs. 45.5% for placebo. Novan...
...fungal culture at day 14 in 61.3% of patients, but did not disclose a p-value. Novan...
...in the mid-dose group (50%, p=0.009) and high-dose group (53.1%, p=0.01) vs. 23.5 for vehicle. Novan...
BioCentury | Apr 12, 2017
Clinical News

Novan gains on Phase II athlete's foot readout

...vehicle. Mycological cure was defined as negative tests for both fungal culture and skin scraping. Novan...
...reported only the high dose’s rate of 58.8% (p<0.05 vs. vehicle). Even with Wednesday's gains, Novan...
...all three endpoints in an identical Phase III study. Following further analysis of the data, Novan...
BioCentury | Apr 7, 2017
Finance

Fade to black

...trial shows no efficacy in combination with Keytruda pembrolizumab to treat advanced or recurrent malignancies Novan Inc....
BioCentury | Apr 1, 2017
Company News

Management tracks

...Novan Inc. (NASDAQ:NOVN) and joined Sienna Biopharmaceuticals Inc. (Westlake Village, Calif.), another dermatology play, as CFO. Novan...
...CFO and SVP of finance and administration at Pozen Inc. , as its interim CFO. Novan...
BioCentury | Feb 3, 2017
Clinical News

SB204: Ph III NI-AC301 and NI-AC302 data

...to develop and commercialize SB204 in Japan to treat acne (see BioCentury, Jan. 23 ). Novan Inc....
...lesion count and time to improvement in IGA Status: Phase III data Milestone: NA Jaime De Leon NVN1000 SB204 Novan Inc. Sato...
BioCentury | Jan 27, 2017
Clinical News

Novan pummeled on Phase III acne miss

...oxide (NO)-releasing compound showed significant efficacy on all three measures in NI-AC302 (p<0.05 for all). Novan...
...on its plans for SB204. Novan declined to comment on the timing of that update. Novan...
...its September 2016 IPO at $11. Its shares traded above $30 on Dec. 7. Jaime De Leon NVN1000 SB204 Novan Inc. Androgen...
Items per page:
1 - 10 of 34